Breakwater Capital Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Breakwater Capital Group’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$303K	Hold	1,007	–	–	0.04%	309
2026 Q1	$333K	Hold	1,007	–	–	0.04%	287
2025 Q4	$400K	Sell	1,007 -20	-2%	-$8.85K	0.06%	257
2025 Q3	$468K	Hold	1,027	–	–	0.07%	231
2025 Q2	$335K	Sell	1,027 -2	-0.2%	-$553	0.05%	269
2025 Q1	$278K	Hold	1,029	–	–	0.05%	278
2024 Q4	$242K	Sell	1,029 -1	-0.1%	-$263	0.05%	262
2024 Q3	$283K	Buy	1,030 +5	+0.5%	+$1.3K	0.06%	243
2024 Q2	$249K	Buy	+1,025	New	+$162K	0.06%	239

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Breakwater Capital Group's ALNY Position: Q2 2026 in Review

Breakwater Capital Group held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2026 at 1,007 shares worth $303K. The position accounts for 0.04% of the portfolio, ranked #309.

Breakwater Capital Group first reported a position in ALNY in Q2 2024 and has held it in 9 quarters since. The position peaked at $468K in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Breakwater Capital Group held 1,007 shares of Alnylam Pharmaceuticals worth $303K as of Q2 2026.
Breakwater Capital Group left its Alnylam Pharmaceuticals share count unchanged in Q2 2026.
Alnylam Pharmaceuticals made up 0.04% of Breakwater Capital Group's portfolio in Q2 2026, its #309 holding.
Breakwater Capital Group first reported a position in Alnylam Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
Breakwater Capital Group's Alnylam Pharmaceuticals position peaked at $468K in Q3 2025.
790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Breakwater Capital Group's 13F filing for Q2 2026, filed 8 Jul 2026.